Leadership Team

Prior to joining us, Mr. Cazergue was Finance & Operations Director at Corin France with responsibilities for coordinating the support functions in a post-acquisition and business recovery environment. Before, he was VP of Finance for EMEA APAC at Resmed, a medical device company. Previous to the above, he was CFO at Sanofi Aventis Turkey where he supported the company’s strong business growth and organizational development. He also was also a key contributor to the local merger process of Rhone Poulenc/HMR and between Sanofi/Aventis. Eric Cazergue holds a Master of Business Administration (MBA) from Emlyon Business School (EM Lyon) in Lyon, France, and a Master’s in Finance and Accounting from the University of Lyon.

Dr. Côté has nearly 20 years of experience in industry with a focus on applying & expanding the use of NGS in the biosafety testing field. She recently was Head of NGS R&D Testing Services at MilliporeSigma, a well-known stakeholder of the biosafety testing and viral vector manufacturing industry. She started her career as a Senior Scientist at Intronn Inc, and then moved to Innovative Biosensors Inc where she developed and engineered biosensors for rapid biodefense and clinical pathogen detection. Colette received her Ph.D. in Molecular Biology, Cell Biology, and Biochemistry from the Brown University and completed her postdoctoral fellowship in the Genetics and Biochemistry Branch at the NIH. She contributed to various papers, publications, and patents throughout her career.

Dr. Binder brings more than 30 years of experience in the Life Sciences industry, combining an understanding of therapeutic product development, technologies, and commercialization. He has a world-wide network based on relationships, successful projects and continuous interaction with companies in North America, Europe and Asia. Dr. Binder’s support for corporate development and M&A activities have benefited from both his technical understanding of the field and his visionary view on future needs of the industry.

Dr. Sébastien Renouf has 20 years of experience in Regulatory Affairs, Quality Assurance, and Safety Control for Cell & Gene Therapy. Before joining PathoQuest, Dr. Renouf was Chief Pharmaceutical Officer at CELLforCURE a CDMO specialized in the CART Cells manufacturing and part of the Novartis Group, where he supported the implementation of inspection and marketing authorization accreditation processes. Dr. Renouf has a Pharmacy degree from Paris XI University and is a Therapeutic Biotechnology graduate from Paris VII University and an internship of the Ile-de-France region with an Industrial and Biomedical Pharmacy specialty.

Dr. Guillaume Deplaine has 10 years of experience in the Biotechnology industry. Prior to joining PathoQuest, Dr. Deplaine was the Quality Control and Analytical Development Head at CELLforCURE a CDMO specialized in CART Cells manufacturing, and was part of the Novartis Group. Before, he was Quality Control Head at THERAVECTYS, a company based on lentiviral technology to develop vaccines. Previous to the above, he was Project manager for medical devices in the genetic diagnosis field. Dr. Deplaine is graduated from the University of Pierre et Marie CURIE/Pasteur Institute and holds a Ph.D in Molecular & Cell Biology. He is co-author of several publications and patents.

Dr. Binder brings more than 30 years of experience in the Life Sciences industry, combining an understanding of therapeutic product development, technologies, and commercialization. He has a world-wide network based on relationships, successful projects and continuous interaction with companies in North America, Europe and Asia. Dr. Binder’s support for corporate development and M&A activities have benefited from both his technical understanding of the field and his visionary view on future needs of the industry.

Mr. Beaufret is the Chief Financial Officer of NBN Co. Limited. He also served as a General Manager of Electrobanqueand. He was Executive in the Ministry of Finance, Deputy Secretary of the international department from 1986 to 1988 and, Deputy Secretary for monetary affairs from 1988 to 1994. He served as General Manager of the French tax administration office since 1997. Mr. Beaufret serves as a Member of the Advisory Board at Aurinvest. He has been Vice Chairman at Sequana S.A., since June 27, 2013, and has been its Independent Director since May 21, 2008. He served as Member of the Supervisory Board at Portigon AG since August 1, 2002. He is a graduate of HEC (Paris Business School) and of the ENA (French National School of Public Administration).